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Highly-active antiretroviral therapy (HAART) can induce a characteristic lipodystrophy syndrome 
characterized by peripheral fat wasting and central adiposity, usually associated with 
hyperlipidaemia and insulin resistance [1,2]. Indirect data have led some authors to propose that 
mitochondrial dysfunction could play a role in this syndrome [3,4].To date, as recently outlined 
by Kakuda et al. [5] in this journal, HIV-infected patients developing lipodystrophy have not been 
studied for mitochondrial changes or respiratory chain capacity. 
We studied a 67-year-old woman with an unremarkable past history except for HIV infection 
diagnosed 5 years earlier, without previous opportunistic infections. During the 4 months before 
the current evaluation, she developed central and peripheral lipodystrophy associated with 
raised serum triglyceride levels (from 130 to 543 mg/dl) and no changes in cholesterolaemia or 
glycaemia. The total CD4 lymphocyte count was 401/mm3, and viral load was 790 copies/mm3. 
She had previously received zidovudine (total cumulative dose; TCD 200 g) and didenosine 
(TCD 216 g) and, when lipodystrophy appeared, she was receiving saquinavir (TCD 1512 g), 
lamivudine (TCD 288 g) and stavudine (TCD 58 g). After obtaining informed consent, a muscle 
biopsy was performed. Some subcutaneous fat lobules were removed during the same surgical 
procedure. Thirty mL of venous blood was extracted for the isolation of lymphocytes. 
A fragment of skeletal muscle was used for histological and ultrastructural studies. The 
biochemical function of the mitochondrial respiratory chain (MRC) was analysed on fresh 
skeletal muscle mitochondria and lymphocyte suspensions using a double method. First, state 
III respiratory rates were pollarographically determined using pyruvate-malate, succinate, 
glycerol-3-phosphate and ascorbate as substrates that transfer electrons at complexes I, II, III 
and IV of MRC, respectively. Intact cell respiration was also assessed for lymphocytes. Second, 
the individual enzyme activity for each complex of the MRC was spectrophotometrically 
quantified. For molecular studies, whole DNA of skeletal muscle, lymphocytes and adipocytes 
were extracted and analysed by Southern blotting and polymerase chain reaction (PCR), to look 
for rearrangements and to quantify mitochondrial DNA (mtDNA) abundance. The methodology 
has been reported elsewhere [6-8]. 
We found abundant lipid storage inside both type I and II myocytes on a histological study of 
skeletal muscle (Fig. 1); the rest of the morphological examination was otherwise irrelevant. With 
respect to biochemical analyses, clearly decreased complex III and IV activities were found in 
both skeletal muscle mitochondria and lymphocytes, which in turn caused a decay in state III 
respiratory rates for nearly all substrates. When mtDNA was analysed, multiple deletions were 
found in skeletal muscle and adipocytes, but not in lymphocytes (Fig. 2), whereas the total 
amount of mtDNA was preserved in all tissues. 
Fig. 1. Skeletal muscle from HIV patient with highly-active antiretroviral therapy-related lipodystrophy. Oil-
red 0 staining shows abundant neutral lipids (up; original magnification: 200×). Lipid droplets are also 
evident in semithin sections (down, original magnification: 800×). 
Fig. 2. Left: Southern blot. Samples were digested with Pvu II, electrophoresed in a 0.8% agarose gel, 
blotted onto nylon membrane, and hybridized with total mitochondrial DNA (mtDNA). The arrow indicates the 
normal 16.5 kb mtDNA bands. CL, Control lymphocytes; CM, control muscle. L, M, and F correspond to 
lymphocytes, muscle and fat from the patient. Muscle and fat from the patient presented abundant multiple 
deletions. Right: Enzyme and oxidative activities from lymphocytes and muscle were decreased (bold 
numbers) for most of the parameters and were evaluated with respect to control values (italic numbers 
between brackets). 
We believe this is the first case of an HIV-infected patient with HAART-related lipodystrophy in 
whom mitochondrial dysfunction was demonstrated. Protease inhibitors have been invoked as 
the main cause of the syndrome through disturbing adipocyte metabolism and causing 
apoptosis by means of altered retinoid signalling [1,9]. In addition, it has also been proposed that 
the well-known mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors [8] 
could contribute to the development of HAART-related lipodystrophy, on the basis of its 
occasional appearance in patients on protease-sparing regimens, and on its similarity with 
multiple symmetrical lipomatosis, a disorder sometimes associated with single and multiple 
mtDNA deletions and decreased complex IV activity [10]. Why the effects of adding protease 
inhibitors to nucleoside analogue reverse transcriptase would produce a lipodystrophy 
syndrome instead of the more classical phenotype resembling an inherited mitochondrial 
disease is not known. We hypothesized that protease inhibitors could interfere with certain 
patient proteases in a selective way in different tissues. In this sense, some proteases are 
essential for mitochondrial biogenesis and function, such as mitochondrial processing of 
peptidases involved in the import and activation of mitochondrial protein precursors (including 
diverse DNA-encoded MRC subunits) synthesized in cytoplasmic ribosomes. 
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